Prognosis and conditional disease-free survival among patients with ovarian cancer

Journal of Clinical Oncology

Volumn 32, Issue 36, 2014, Pages 4102-4112

  Kurta, Michelle L ^a   Edwards, Robert P ^b,c,d   Moysich, Kirsten B ^e   McDonough, Kathleen ^c   Bertolet, Marnie ^a,b   Weissfeld, Joel L ^a,c   Catov, Janet M ^a,b   Modugno, Francesmary ^a,b,d   Bunker, Clareann H ^a   Ness, Roberta B ^f   Diergaarde, Brenda ^a,c  

^a GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

^e ROSWELL PARK CANCER INSTITUTE   (United States)

^f UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CA 125 ANTIGEN; CARBOPLATIN; CATUMAXOMAB; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; GEMCITABINE; INTERFERON; OREGOVOMAB; OXALIPLATIN; PACLITAXEL; PACLITAXEL POLIGLUMEX; TOPOTECAN;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER REGRESSION; CASE CONTROL STUDY; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DISEASE FREE SURVIVAL; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; LIFESTYLE; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVARY CANCER; PERITONEUM CANCER; PREDICTION; SURVIVAL RATE; SURVIVAL TIME; UTERINE TUBE TUMOR; BLOOD; MIDDLE AGED; MORTALITY; OVARY TUMOR; PROGNOSIS; PROPORTIONAL HAZARDS MODEL;

ADULT; AGED; CA-125 ANTIGEN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS;

EID: 84919713129     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.55.1713     Document Type: Article

References (43)

1. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63:11-30, 2013
2. Howlader N, Noone AM, Krapcho M, et al: SEER Cancer Statistics Review, 1975-2010, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975-2010/,
3. Choi M, Fuller CD, Thomas CR Jr, et al: Conditional survival in ovarian cancer: Results from the SEER dataset 1988-2001. Gynecol Oncol 109:203-209, 2008
4. Merrill RM, Hunter BD: Conditional survival among cancer patients in the United States. Oncologist 15:873-882, 2010
5. Gloeckler Ries LA, Reichman ME, et al: Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program. Oncologist 8:541-552, 2003
6. Janssen-Heijnen ML, Gondos A, Bray F, et al: Clinical relevance of conditional survival of cancer patients in Europe: Age-specific analyses of 13 cancers. J Clin Oncol 28:2520-2528, 2010
7. Miller RE, Rustin GJ: How to follow-up patients with epithelial ovarian cancer. Curr Opin Oncol 22:498-502, 2010
8. Gadducci A, Fuso L, Cosio S, et al: Are surveillance procedures of clinical benefit for patients treated for ovarian cancer? A retrospective Italian multicentric study. Int J Gynecol Cancer 19:367-374, 2009
9. Tanner EJ, Chi DS, Eisenhauer EL, et al: Surveillance for the detection of recurrent ovarian cancer: Survival impact or lead-time bias? Gynecol Oncol 117:336-340, 2010
10. Rustin GJ, van der Burg ME, Griffin CL, et al: Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): A randomised trial. Lancet 376:1155-1163, 2010
11. Ness RB, Dodge RC, Edwards RP, et al: Contraception methods, beyond oral contraceptives and tubal ligation, and risk of ovarian cancer. Ann Epidemiol. 21:188-196, 2011
12. Kurta ML, Moysich KB, Weissfeld JL, et al: Use of fertility drugs and risk of ovarian cancer: Results from a U.S.-based case-control study. Cancer Epidemiol Biomarkers Prev 21:1282-1292, 2012
13. Henson DE, Ries LA: On the estimation of survival. Semin Surg Oncol 10:2-6, 1994
14. Zabor EC, Gonen M, Chapman PB, et al: Dynamic prognostication using conditional survival estimates. Cancer 119:3589-3592, 2013
15. Zamboni BA, Yothers G, Choi M, et al: Conditional survival and the choice of conditioning set for patients with colon cancer: An analysis of NSABP trials C-03 through C-07. J Clin Oncol 28:2544-2548, 2010
16. Anderson JR, Cain KC, Gelber RD: Analysis of survival by tumor response. J Clin Oncol 1:710-719, 1983
17. Anderson JR, Cain KC, Gelber RD: Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables. J Clin Oncol 26:3913-3915, 2008
18. Ji J, Försti A, Sundquist J, et al: Survival in ovarian cancer patients by histology and family history. Acta Oncol 47:1133-1139, 2008
19. Rubin SC, Randall TC, Armstrong KA, et al: Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings. Obstet Gynecol 93:21-24, 1999
20. Omura GA, Brady MF, Homesley HD, et al: Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: The Gynecologic Oncology Group experience. J Clin Oncol 9:1138-1150, 1991
21. Halperin R, Zehavi S, Langer R, et al: Primary peritoneal serous papillary carcinoma: A new epidemiologic trend? A matched-case comparison with ovarian serous papillary cancer. Int J Gynecol Cancer 11:403-408, 2001
22. Hoskins WJ, Bundy BN, Thigpen JT, et al: The influence of cytoreductive surgery on recurrencefree interval and survival in small-volume stage III epithelial ovarian cancer: A Gynecologic Oncology Group study. Gynecol Oncol 47:159-166, 1992
23. Marszalek A, Alran S, Scholl S, et al: Outcome in advanced ovarian cancer following an appropriate and comprehensive effort at upfront cytoreduction: A twenty-year experience in a single cancer institute. Int J Surg Oncol 2010:214919, 2010
24. Winter WE 3rd, Maxwell GL, Tian C, et al: Prognostic factors for stage III epithelial ovarian cancer: A Gynecologic Oncology Group Study. J Clin Oncol 25:3621-3627, 2007
25. Zorn KK, Tian C, McGuire WP, et al: The prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma: A Gynecologic Oncology Group study. Cancer 115:1028-1035, 2009
26. Markman M, Liu PY, Rothenberg ML, et al: Pretreatment CA-125 and risk of relapse in advanced ovarian cancer. J Clin Oncol 24:1454-1458, 2006
27. Eitan R, Levine DA, Abu-Rustum N, et al: The clinical significance of malignant pleural effusions in patients with optimally debulked ovarian carcinoma. Cancer 103:1397-1401, 2005
28. Mironov O, Ishill NM, Mironov S, et al: Pleural effusion detected at CT prior to primary cytoreduction for stage III or IV ovarian carcinoma: Effect on survival. Radiology 258:776-784, 2011
29. Zuna RE, Behrens A: Peritoneal washing cytology in gynecologic cancers: Long-term follow-up of 355 patients. J Natl Cancer Inst 88:980-987, 1996
30. Brun JL, Feyler A, Chene G, et al: Long-term results and prognostic factors in patients with epithelial ovarian cancer. Gynecol Oncol 78:21-27, 2000
31. Burghardt E, Girardi F, Lahousen M, et al: Patterns of pelvic and paraaortic lymph node involvement in ovarian cancer. Gynecol Oncol 40:103-106, 1991
32. di Re F, Baiocchi G, Fontanelli R, et al: Systematic pelvic and paraaortic lymphadenectomy for advanced ovarian cancer: Prognostic significance of node metastases. Gynecol Oncol 62:360-365, 1996
33. Panici PB, Maggioni A, Hacker N, et al: Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: A randomized clinical trial. J Natl Cancer Inst 97:560-566, 2005
34. Gerestein CG, Eijkemans MJ, de Jong D, et al: The prediction of progression-free and overall survival in women with an advanced stage of epithelial ovarian carcinoma. BJOG 116:372-380, 2009
35. Gupta D, Lis CG: Role of CA125 in predicting ovarian cancer survival: A review of the epidemiological literature. J Ovarian Res 2:13, 2009
36. Skaznik-Wikiel ME, Sukumvanich P, Beriwal S, et al: Possible use of CA-125 level normalization after the third chemotherapy cycle in deciding on chemotherapy regimen in patients with epithelial ovarian cancer: Brief report. Int J Gynecol Cancer 21:1013-1017, 2011
37. van Dalen A, Favier J, Burges A, et al: Prognostic significance of CA 125 and TPS levels after 3 chemotherapy courses in ovarian cancer patients. Gynecol Oncol 79:444-450, 2000
38. McGuire WP, Hoskins WJ, Brady MF, et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1-6, 1996
39. Burger RA, Brady MF, Bookman MA, et al: Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365:2473-2483, 2011
40. Abaid LN, Goldstein BH, Micha JP, et al: Improved overall survival with 12 cycles of single-agent paclitaxel maintenance therapy following a complete response to induction chemotherapy in advanced ovarian carcinoma. Oncology 78:389-393, 2010
41. Markman M, Liu PY, Wilczynski S, et al: Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 21:2460-2465, 2003
42. Rustin GJ: Follow-up with CA125 after primary therapy of advanced ovarian cancer has major implications for treatment outcome and trial performances and should not be routinely performed. Ann Oncol 22:viii45-viii8, 2011 (suppl 8)
43. Oskay-Oezcelik G, du Bois A, Fasching PA, et al: What do patients think about CA-125 monitoring in the follow-up? Results from a multicenter trial in 1,060 patients with ovarian cancer. J Clin Oncol 27:282s, 2009 (suppl 15; abstr 5522)